Pulmonx (LUNG) Common Equity (2019 - 2025)

Pulmonx (LUNG) has 7 years of Common Equity data on file, last reported at $54.1 million in Q4 2025.

• On a quarterly basis, Common Equity fell 36.93% year-over-year to $54.1 million in Q4 2025; TTM through Dec 2025 was $54.1 million, a 36.93% decrease from a year earlier, with the FY2025 full-year figure at $54.1 million, down 36.93% from the prior year.
• Common Equity for Q4 2025 stood at $54.1 million, down from $60.0 million in the prior quarter.
• Over the last five years, Common Equity for LUNG reached as high as $216.1 million in Q1 2021 and fell as low as $54.1 million in Q4 2025.
• Historically, Common Equity has averaged $133.4 million across 5 years, with a median of $129.8 million in 2023.
• Across the five-year window, Common Equity soared 211.39% in 2021 and tumbled 36.93% in 2025, its largest moves.
• Year by year, Common Equity stood at $193.2 million in 2021, then declined by 20.3% to $154.0 million in 2022, then retreated by 23.18% to $118.3 million in 2023, then fell by 27.47% to $85.8 million in 2024, then plunged by 36.93% to $54.1 million in 2025.
• Per Business Quant data, the three most recent Common Equity figures were $54.1 million in Q4 2025, $60.0 million in Q3 2025, and $69.1 million in Q2 2025.